Search the Newsreel

Burning Rock Biotech (BNR) Slides 4% as Biotech Sentiment Wavers — Key Levels in Focus - On Balance Volume

RBC Adjusts Price Target on Legend Biotech to $58 From $59, Maintains Outperform Rating

RBC Capital Markets has adjusted its price target for Legend Biotech (LEGN) to $58, down from $59, while reiterating an Outperform rating on the stock. This revision comes amidst recent news for Legend Biotech, including a downgrade from Oppenheimer and the company reporting its …

Legend Biotech Releases Q2 2026 Financial Results

Legend Biotech (LEGN) reported strong Q2 2026 financial results, with adjusted earnings of $0.16 per share, surpassing estimates. The company generated $387.5 million in revenue, largely driven by its CARVYKTI collaboration, indicating significant growth and market penetration for its cell therapy platform. Wall Street …

Legend Turns Profitable In Q2 As CARVYKTI Sales Jump By 50%

(RTTNews) - Legend Biotech Corporation (LEGN) released financial results for the second quarter ended June 30, 2026. The commercial-stage company turned profitable in the second quarter, compared with a loss in the prior-year quarter, driven by higher collaboration revenue and improved operating income. For …

Legend Biotech (LEGN) Stock Rebounds As Profit Arrives But Carvykti Risk Persists

Legend Biotech (NASDAQ: LEGN) surges on CARVYKTI growth and Q2 2026 profitability

Legend Biotech reported strong financial results for Q2 2026, achieving profitability with $33.2 million in net income, driven by a 50% increase in CARVYKTI sales to approximately $657 million. The company's total revenue rose to $387.5 million, significantly improving from a net loss in …

Riot Platforms (RIOT) Stock Jumps As AI Leases Eclipse Mounting Losses

First Tracks Biotherapeutics Ord Shs (TRAX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Legend Biotech (LEGN) Returned To Profit, Is The Stock Still Cheap?

Precision Trading with Samsara Inc. Class A (IOT) Risk Zones

This article provides an in-depth analysis of Samsara Inc. Class A (NYSE: IOT) with a focus on risk zones and trading strategies generated by AI models. It highlights strong near and mid-term sentiment, a weak long-term outlook, and presents specific strategies for position trading, …

Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity Deal - What's Changed

Sana Biotechnology (SANA) saw its stock rise by 13.5% after reporting narrower losses in Q2 2026 and announcing a significant collaboration with the Mayo Clinic, which includes a $25 million equity investment. The company also made progress in its clinical trial programs and released …

Riot Platforms agrees 191MW, 20-year lease agreement with Anthropic worth $9.1bn – report

Riot Platforms, a US-based Bitcoin mining firm, has secured a 20-year, $9.1 billion deal to lease 191MW of data center capacity at its Rockdale, Texas campus. Bloomberg reported the customer as Anthropic. The agreement includes options for two five-year extensions, potentially increasing the total …

PDS Biotechnology Halts PDS0101 Trial, Pivots to PDS0301 in Colorectal Cancer

PDS Biotechnology has announced the halt of its PDS0101 trial and internal investment, including the discontinuation of the Phase 3 VERSATILE-003 trial, to pivot its resources towards PDS0301. PDS0301, a tumor-targeted IL-12 immunocytokine, will now be the company's lead asset with a priority indication …

Lakefront Biotherapeutics (ENXTAM:LKFT) Stock Reflects Profit Fragility After Revenue Reset

Iovance Biotherapeutics (IOVA) Stock Looks Fairly Valued Despite 222% Returns

Iovance Biotherapeutics (IOVA) stock has seen a significant 221.8% return over the past year, but its current valuation suggests it is now fairly priced rather than cheap. The company scores a mixed 4 out of 6 on Simply Wall St's valuation checks, with a …

What Is Riot Platforms (RIOT) Becoming With Its $9.1 Billion AI Lease?

Why Riot Platforms (RIOT) Is Down 6.1% After Striking a $9.1 Billion AI Data Center Deal

In August 2026, Riot Platforms reported second-quarter 2026 results showing revenue of US$174.24 million but a net loss of US$237.17 million, driven in part by almost US$27.97 million of impairment charges, while bitcoin production rose to 1,587 coins. On the same day, the company …

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Interim Chief Executive Officer - Alan BashChief Financial Officer - Carlos SantosInterim Head of R&D - Yuhong QiuDirector of Investor Relations - Caroline LeCates Paul TAKEAWAYS Worldwide Net …

Avecho Biotechnology Cuts Shareholder Numbers via Small Holding Sale Facility

Patriot Resources Secures Key Community Access for Tassa Silver-Gold Work

RTW Biotech Opportunities (RTWG) Supports Avere Therapeutics’ $820M Capital Raise and NextCure Reverse Merger

FBIO Looks 125.0% Overvalued on GF Value™ Ahead of Q2 Earnings

Fortress Biotech (NASDAQ: FBIO) is set to release its Q2 earnings report on August 12, 2026, with analysts forecasting an EPS of -$0.20 and revenue of $18.3 million. The stock is currently deemed 125.0% overvalued by GuruFocus' GF Value™ metric, trading at $2.61 against …

Iovance Biotherapeutics (IOVA) Is Up 48.3% After Narrowing Losses And Reaffirming 2026 Revenue Guidance

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Legend Biotech Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LEGN) 2026-08-11

This article first appeared on GuruFocus. Total Revenue: Increased 52% year over year, driven by continued CARVYKTI demand and commercial expansion. CARVYKTI Net Trade Sales: Approximately $657 million worldwide, representing 50% year-over-year growth and 10% sequential growth. U.S. CARVYKTI Sales: Increased 32% year over …

Arcutis insider plans sale of 15,000 shares | ARQT SEC Filing - Form 144

Arcutis Biotherapeutics (ARQT) insider Patrick Burnett has filed a Form 144 to sell 15,000 shares of common stock through Merrill Lynch on or after August 11, 2026. These shares were acquired via a stock option exercise on January 12, 2024. Burnett previously sold 955 …

RIOT Stock Pops As Massive AI Data Center Deal Follows Earnings Beat

Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot

Bolt Biotherapeutics Inc. (BOLT) reported a second-quarter loss of $7.7 million, or $4.57 per share. The company generated $5,000 in revenue during the period. Bolt Biotherapeutics shares closed at $4.02 on Tuesday, down from $5.63 a year ago.

Bolt Biotherapeutics' Cancer Trial Data Expected With Q3 Results

Bolt Biotherapeutics (BOLT) reported Q2 2026 financial results with collaboration revenue of $5 thousand and a net loss of $7.7 million, noting reduced R&D and G&A expenses. The company's lead ISAC candidate, BDC-4182, is progressing in a Phase 1/2 trial for gastric and gastroesophageal …

Bolt Biotherapeutics, Inc. Q2 2026: Revenue $5K, Net loss $(7.72M), EPS $(4.57) — 10-Q Summary

Bolt Biotherapeutics, Inc. reported minimal revenue of $5K for Q2 2026, a sharp decline from the previous year, with a net loss of $(7.72M) and diluted EPS of $(4.57). The company's revenue drop was attributed to reduced collaboration activity, while cost reductions slightly narrowed …

Riot Platforms, Inc. (RIOT) Reports Q2 Loss, Tops Revenue Estimates

Riot Platforms, Inc. (RIOT) reported a Q2 loss of $0.68 per share, missing the Zacks Consensus Estimate of a $0.39 loss, but exceeded revenue expectations with $174.24 million. Despite outperforming the market year-to-date, the company currently holds a Zacks Rank #5 (Strong Sell) due …

Bolt Biotherapeutics (BOLT) flags going concern risk as losses fall and cash nears $18M

Windlas Biotech Shares Surge Over 12% Following Strong Q1 Top-Line Growth

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Given Average Rating of "Hold" by Analysts

Lakefront Biotherapeutics (NASDAQ:LKFT) has received an average "Hold" rating from analysts, with a consensus 12-month price target of $34.33. The company recently surpassed earnings expectations, reporting an EPS of $0.04 against an anticipated loss of $0.97, and revenue of $15.47 million, significantly higher than …

Legend Biotech Corp (LEGN) (Q2 2026) Earnings Call Highlights: First Profitable Quarter Driven ...

This article first appeared on GuruFocus. Total Revenue: Increased 52% year over year, driven by continued CARVYKTI demand and commercial expansion. CARVYKTI Net Trade Sales: Approximately $657 million worldwide, representing 50% year-over-year growth and 10% sequential growth. U.S. CARVYKTI Sales: Increased 32% year over …

PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program

PDS Biotechnology Corporation's stock crashed by approximately 67% after the company announced a strategic refocus of its resources towards the PDS0301 program for metastatic colorectal cancer. This shift is based on encouraging clinical data and a belief that PDS0301 offers a more attractive path …